Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. - Wikidata - awgldk - TriplyDB

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

http://www.wikidata.org/entity/Q35136824

about

Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples.Anaplastic lymphoma kinase (ALK) gene alteration in gastric signet ring cell carcinoma.

P2860

Q36351953-BE172FB7-345C-4BD3-A6A1-E8904B900651 Q53692985-C6C13F6B-6606-43E3-993E-41F9F3BCDE03

P2860

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

http://www.wikidata.org/entity/Q35136824

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract.

@ast

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract.

@en

type

label

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract.

@ast

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract.

@en

prefLabel

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract.

@ast

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract.

@en

P1433

Q35136824-52718497-BB24-4AA3-A218-00ABEE20845D

P1476

Q35136824-832E1B11-F716-4C49-A5E4-297D2EB9BDE7

P2093

Q35136824-2CD6F17A-898B-4E8D-9B46-39D2C2A0FCE4

Q35136824-33F932F7-38BE-46D7-86CF-71A01D65AF5A

Q35136824-52229FC0-796C-4D0B-8BC8-36FDCC785CBA

Q35136824-605B8B76-BF6B-438F-8FCB-312A382A5DF4

Q35136824-71CA59D4-6315-46CE-8F59-229CEAB73C84

Q35136824-8368BB3E-5616-4D29-9829-F47DF0246726

Q35136824-83CD7F82-8E12-4280-A231-39C5F5AF062B

Q35136824-99F5B11B-72FE-45BD-9EAE-4E6B364375EB

Q35136824-A9B66F59-DA56-4ACA-908E-27E3DDF5D977

Q35136824-B2F9270C-E953-404A-A8B6-9ECD62C91222

P2860

Q35136824-0A1D185E-1565-4B4E-B61D-FA806FA5A3CD

Q35136824-109A8996-219A-4333-A248-DCDE7407ACA0

Q35136824-12BA8A4E-B513-473D-A8E2-C36C727D34B6

Q35136824-156A8303-13A6-4046-B3A4-4374FCE03A7D

Q35136824-15EEE9C4-2C50-4E2A-85DB-C09BECE26489

Q35136824-1662348B-91A8-40A8-8459-C095D4DE3BF8

Q35136824-28A1DD67-82C8-4B86-BEB6-FA583D5FA4D8

Q35136824-4D80359C-3E1E-48A0-80EB-DBD6AD994B79

Q35136824-51A11C60-102C-45AA-A859-5BB18167C48D

Q35136824-59EBB5DF-F8C4-42D0-87C9-E500E109AB14

P304

Q35136824-9047A322-FEC3-4CED-852E-EA8628C2C6A9

P31

Q35136824-5DD9D747-C8F1-49E6-9761-F9FDF494FC30

P356

Q35136824-556CB1E2-8B1E-4863-87F1-5ED02082224A

P433

Q35136824-784F000F-E907-42A4-BBDC-727FB69B21C8

P478

Q35136824-7A2C9C70-5BC0-4E04-A9E6-8CDC39F5E292

P50

Q35136824-DAAE1130-2030-4D4C-9B7B-062E9136F859

P577

Q35136824-354EE3D1-DCD4-4867-B205-5E2B3C3B7D6A

P5875

Q35136824-E8790C60-81ED-460B-B954-AA4744796805

P698

Q35136824-BB4EE0D6-7FF8-44AA-8C29-43F395E054E1

P932

Q35136824-63532AD3-39AB-466A-925B-C5EC7802AE76

P356

1758834014567117

P1433

Therapeutic advances in medical oncology

P1476

Anaplastic lymphoma kinase (AL ...... of the gastrointestinal tract

@en

P2093

Bassel F El-Rayes

http://www.w3.org/2001/XMLSchema#string

Dianne Alexis

http://www.w3.org/2001/XMLSchema#string

Fadlo R Khuri

http://www.w3.org/2001/XMLSchema#string

Francisco G La Rosa

http://www.w3.org/2001/XMLSchema#string

Gabriel Sica

http://www.w3.org/2001/XMLSchema#string

Guojing Zhang

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Michael R Rossi

http://www.w3.org/2001/XMLSchema#string

Olatunji B Alese

http://www.w3.org/2001/XMLSchema#string

Taofeek K Owonikoko

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

P304

56-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834014567117

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273385121

http://www.w3.org/2001/XMLSchema#string

P698

25755678

http://www.w3.org/2001/XMLSchema#string

P932

4346214

http://www.w3.org/2001/XMLSchema#string